文献速递肝病消化内镜消化道出血

慢性丙肝代偿期肝硬化患者内镜筛查静脉曲张的 uptake 及出血相关因素:2005-2016 年全国数据库链接研究

Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study.
PubMed 文献 · Aliment Pharmacol Ther · 2019-06-03

该研究基于苏格兰丙肝临床数据库链接全国住院与死亡记录,纳入 2005-2016 年诊断代偿期肝硬化的慢性 HCV 患者 2741 例,分析内镜筛查 uptake 及首次静脉曲张出血相关因素。结果显示约 34% 在肝硬化诊断前后 12 个月内接受筛查,筛查比例从 2005-2010 年的 42% 降至 2014-2016 年的 26%;病毒清除与首次静脉曲张出血风险降低相关(HR=0.56,95%CI:0.32-0.97)。

要点

  • 约 34% 患者在肝硬化诊断前后 12 个月内接受内镜筛查。
  • 筛查比例从 2005-2010 年的 42% 降至 2014-2016 年的 26%。
  • 病毒清除与首次静脉曲张出血风险降低相关(HR=0.56)。

核心结论

  • 肝硬化诊断后内镜筛查总体 uptake 低,近年下降令人担忧。
  • 首次静脉曲张出血风险随时间保持稳定,可能归因于持续预防措施及诊断程序变化导致近年患者池病情更轻。

研究设计与样本

  • 苏格兰丙肝临床数据库链接全国住院和死亡记录,纳入 2005-2016 年诊断代偿期肝硬化的慢性 HCV 患者 n=2741。
  • 采用 logistic 回归估计按日历年时期筛查的调整比值比,采用 Cox 回归估计首次静脉曲张出血的调整风险比(HR)。

主要发现

  • 约 34% 在肝硬化诊断前 12 个月至诊断后 12 个月期间接受筛查。
  • 筛查比例 2005-2010 年为 42%,2011-2013 年降至 37%,2014-2016 年降至 26%。
  • 与 2008-2010 年相比,年龄 <40 岁(OR=0.61,95%CI:0.48-0.77)和 60+ 岁(OR=0.67,95%CI:0.48-0.94)、有抗病毒治疗史(OR=0.70,95%CI:0.55-0.89)、2014-2015 年诊断肝硬化(OR=0.67,95%CI:0.52-0.86)的筛查 odds 降低。
  • 与 2008-2010 年相比,其他时期首次静脉曲张出血的相对风险无增加/降低证据,但病毒清除与较低风险相关(HR=0.56,95%CI:0.32-0.97)。

临床怎么用

  • 关注代偿期 HCV 肝硬化患者的内镜筛查 uptake,尤其是近年筛查比例下降。
  • 病毒清除与首次静脉曲张出血风险降低相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary measures for preventing morbidity and mortality associated with bleeding gastroesophageal varices in cirrhotic patients include endoscopic screening. AIM: To identify factors associated with (a) screening and (b) first hospital admission for variceal bleeding among cirrhotic hepatitis C virus (HCV) patients attending specialist care in Scotland. METHODS: The Scottish Hepatitis C Clinical Database was linked to national hospitalisation and deaths records to identify all chronic HCV patients diagnosed with compensated cirrhosis in 2005-2016 (n = 2741). The adjusted odds of being screened by calendar year period were estimated using logistic regression, and the adjusted hazard ratio (HR) of a first variceal bleed using Cox regression. RESULTS: About 34% were screened within the period starting 12 months before and ending 12 months after cirrhosis diagnosis. The proportion screened was stable in 2005-2010 at 42%, declining to 37% in 2011-2013 and 26% in 2014-2016. Odds of screening were decreased for age-groups <40 (OR = 0.61, 95% CI: 0.48-0.77) and 60+ years (OR = 0.67, 95% CI: 0.48-0.94), history of antiviral therapy (OR = 0.70, 95% CI: 0.55-0.89), and cirrhosis diagnosis in 2014-2015, compared with 2008-2010 (OR = 0.67, 95% CI: 0.52-0.86). Compared with 2008-2010, there was no evidence for an increased/decreased relative risk of a first variceal bleed in any other period, but viral clearance was associated with a lower risk (HR = 0.56, 95% CI: 0.32-0.97). CONCLUSIONS: Overall screening uptake following cirrhosis diagnosis was low, and the decline in recent years is of concern. The stable bleeding risk over time may be attributable both to ongoing prevention initiatives and to changing diagnostic procedures creating a patient pool with milder disease in more recent years.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. McDonald SA, Barclay ST, Hutchinson SJ, et al. Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. Aliment Pharmacol Ther. 2019. PMID: 31157411. doi:10.1111/apt.15320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。